However, subsequent analysis of CDK18 protein levels in the Nottingham Tenovus breast cancer cohort revealed better survival in ER- tumours that have higher than median levels of CDK18, which is also true in ER- MDA-MB-231 breast cancer cell lines overexpressing endogenous CDK18 when treated with chemotherapeutic agents. This evidence concerns the gene CDK18 and breast carcinoma.